One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Open Access
- 28 August 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0356906
Abstract
Idarubicine is a mainstay of the treatment strategy for hematological cancer. The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies. The aim of the present work is to establish the stability of idarubicin preparations diluted in polyolefin-type bags (Freeflex + ®) for intravenous administration in hematological clinical settings. Preparations were produced by diluting Zavedos® idarubicin in Freeflex + ® bags containing 0.9% sodium chloride (NaCl) or 5% dextrose (Dex) at concentrations of 0.04 mg/mL and 0.2 mg/mL. These preparations were stored at 5 ± 3 °C or 22 ± 3 °C. Three bags were prepared to evaluate each condition, for a total of 24 bags. To assess chemical stability, a stability-indicating high pressure liquid chromatography-ultraviolet/visible diode array detector assay was used. Samples were assayed on days D0, D1, D2, D7, D15, D22 and D30. A physical stability study was carried out on days D0, D15 and D30, looking for visible and sub-visible particles, measuring pH and osmolality. During the study, sample concentrations remained above 95% of the initial concentration, and no degradation products were detected. No color change or precipitation were observed with the naked eye. Sub-visible particles count remained below recommended limits. The pH and osmolality values remained unchanged from D0. This study demonstrates the stability of idarubicin, diluted to concentrations between 0.04 and 0.2 mg/mL in solutions of 0.9% NaCl and 5% Dex, stored at 5 ± 3 °C or 22 ± 3 °C for 30 days.Keywords
This publication has 9 references indexed in Scilit:
- Doxorubicin Stability-indicating Method and its Main Degradation Products In vitro ToxicityThe AAPS Journal, 2025
- Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolizationJournal of Pharmaceutical and Biomedical Analysis, 2022
- The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemiaMedicine, 2020
- Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinomaWorld Journal of Gastroenterology, 2020
- Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysisClinical Lymphoma Myeloma and Leukemia, 2018
- Characterization of degradation products of idarubicin through LC-UV, MSn and LC–MS-TOF studiesJournal of Pharmaceutical and Biomedical Analysis, 2013
- A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluidsJournal of Pharmaceutical and Biomedical Analysis, 2013
- Guidelines for the practical stability studies of anticancer drugs: a European consensus conference: Table 1European Journal of Hospital Pharmacy, 2012
- Viability of microorganisms in novel antineoplastic and antiviral drug solutionsJournal of Oncology Pharmacy Practice, 1998